First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses

Published:2016-11-28 Issue:1 Volume:13 Page:
ISSN:1742-4690
Container-title:Retrovirology
language:en
Short-container-title:Retrovirology

Author:

Choi Eunsil,Michalski Chad J.,Choo Seung Ho,Kim Gyoung Nyoun,Banasikowska Elizabeth,Lee Sangkyun,Wu Kunyu,An Hwa-Yong,Mills Anthony,Schneider Stefan,Bredeek U. Fritz,Coulston Daniel R.,Ding Shilei,Finzi Andrés,Tian Meijuan,Klein Katja,Arts Eric J.,Mann Jamie F. S.,Gao Yong,Kang C. Yong

Funder

National Research Council of Canada Industrial Research Assistant Program

Sumagen Canada

National Institutes of Health

CIHR

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Virology

Link

http://link.springer.com/content/pdf/10.1186/s12977-016-0317-2.pdf

Reference45 articles.

1. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983;220:868–71.

2. Khowsroy K, Dhitavat J, Sabmee Y, Laowarakul P, Wattanakitwichai J, Auetian J, et al. Expectation of volunteers towards the vaccine efficacy of the prime-boost HIV vaccine phase III trial during unblinding. AIDS Res Hum Retrovir. 2014;30:1041–5.

3. Plotkin SA. The RV144 Thai HIV vaccine trial. Hum Vaccines. 2010;6:159.

4. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209–20.

5. Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis. 2012;12:531–7.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Question of HIV Vaccine: Why Is a Solution Not Yet Available?;Journal of Immunology Research;2024-04-08

2. Future prospects in mRNA vaccine development;Biomedical Materials;2023-08-17

3. Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV;Vaccines;2023-05-12

4. Human Immunodeficiency Virus Vaccines;Plotkin's Vaccines;2023

5. The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines;Health Policy and Technology;2022-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3